Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin–specific clinical impact
-
- Daisuke Ennishi
- Centre for Lymphoid Cancer,
-
- Anja Mottok
- Centre for Lymphoid Cancer,
-
- Susana Ben-Neriah
- Centre for Lymphoid Cancer,
-
- Hennady P. Shulha
- Centre for Lymphoid Cancer,
-
- Pedro Farinha
- Centre for Lymphoid Cancer,
-
- Fong Chun Chan
- Centre for Lymphoid Cancer,
-
- Barbara Meissner
- Centre for Lymphoid Cancer,
-
- Merrill Boyle
- Centre for Lymphoid Cancer,
-
- Christoffer Hother
- Centre for Lymphoid Cancer,
-
- Robert Kridel
- Centre for Lymphoid Cancer,
-
- Daniel Lai
- Molecular Oncology, and
-
- Saeed Saberi
- Molecular Oncology, and
-
- Ali Bashashati
- Molecular Oncology, and
-
- Sohrab P. Shah
- Molecular Oncology, and
-
- Ryan D. Morin
- Genome Science Centre, British Columbia Cancer Agency, Vancouver, BC, Canada
-
- Marco A. Marra
- Genome Science Centre, British Columbia Cancer Agency, Vancouver, BC, Canada
-
- Kerry J. Savage
- Centre for Lymphoid Cancer,
-
- Laurie H. Sehn
- Centre for Lymphoid Cancer,
-
- Christian Steidl
- Centre for Lymphoid Cancer,
-
- Joseph M. Connors
- Centre for Lymphoid Cancer,
-
- Randy D. Gascoyne
- Centre for Lymphoid Cancer,
-
- David W. Scott
- Centre for Lymphoid Cancer,
説明
<jats:title>Key Points</jats:title> <jats:p>MYC and BCL2 genetic alterations are associated with COO subtype-specific clinical effect in R-CHOP-treated DLBCL.</jats:p>
収録刊行物
-
- Blood
-
Blood 129 (20), 2760-2770, 2017-05-18
American Society of Hematology
